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Background/aim: Avascular necrosis (AVN) is the death of bone due to compromise of blood flow. The etiology of AVN is multifactorial;
corticosteroid usage is the second most significant factor after trauma, and systemic lupus erythematosus (SLE) is the most common
underlying disease. The objective of this study was to assess the factors of AVN in SLE patients.
Materials and methods: The study included 127 patients with SLE who fulfilled 1997 American College of Rheumatology (ACR) revised
criteria. Demographic data, age at SLE diagnosis, disease duration, disease activity, body mass index, clinical findings, antiphospholipid
syndrome, steroid usage, dose and duration, comorbid diseases, and smoking history were recorded.
Results: AVN was found in 11 of 127 (8.7%) SLE patients. Hyperlipidemia (P < 0.001), cushingoid body habitus (P < 0.001), and
proteinuria (P = 0.013) were found at higher rates in the AVN group. All of the 11 AVN cases had osteoporosis (P < 0.02). In multivariate
regression analysis, daily steroid usage was the only factor for development of AVN in SLE.
Conclusion: The hypothesis of our study was that an alternate day steroid regimen may decrease AVN frequency in SLE patients.
Key words: Avascular necrosis, alternate day steroid usage, systemic lupus erythematosus

1. Introduction
Avascular necrosis (AVN) is bone death due to
compromise of blood flow that leads to arthralgia,
bone destruction, and loss of function in the joint.
AVN etiology is multifactorial, and steroid usage
is the second most important factor after trauma.
Systemic lupus erythematosus (SLE) is the most
common underlying disease in AVN [1]. In 1960,
Dubois and Cozen reported AVN in SLE patients
[2]. The prevalence of AVN in SLE patients is around
3%–52%, according to diagnostic methods and
evaluation of symptomatic or asymptomatic patients
[3]. The risk factors for AVN in SLE patients were
shown to be young age, sex, cushingoid body habitus,
Raynaud’s phenomenon, thrombophlebitis, vasculitis,
nephritis, cerebritis, interstitial pneumonitis, pleural
effusion, antiphospholipid syndrome, preeclampsia,
hypertension, anemia, thrombocytopenic thrombotic
purpura, smoking, and migraine [4]. The objective of
this study was to evaluate associated factors for the
development of AVN in our SLE cohort.

2. Materials and methods
A total of 127 consecutive SLE patients (86.6% female) were
enrolled in this cross-sectional study during 10 months
in our outpatient clinic. Ethical approval was received
from the local ethical committee. Inclusion criteria of this
study were being ≥18 years old and fulfillment of the 1997
American College of Rheumatology (ACR) revised criteria
for the classification of SLE [5].
Demographic data, clinical, and laboratory features
were recorded from a standard questionnaire and from
the patients’ files. Potential associated factors of AVN
such as sex, age, body mass index, age at disease diagnosis,
disease duration, smoking history, hypertension, diabetes
mellitus, coronary artery disease, hyperlipidemia, anemia,
osteoporosis, menopause, SLE disease activity score,
antiphospholipid antibodies positivity, and corticosteroid
usage were noted.
SLE disease activity index score (SLEDAI-2K) [6] was
recorded for assessment of disease activity. SLEDAI scores
were also calculated according to the situation 6 months
prior to AVN diagnosis.
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Cases with antiphospholipid syndrome were defined
according to the 1999 classification criteria [7]. Lupus
anticoagulant positivity and/or anticardiolipin antibody
positivity were recorded one by one separately. Anti-beta 2
glycoprotein I antibodies could not be evaluated.
The corticosteroid usage of the patients was analyzed
very carefully, from SLE diagnosis to introduction to the
study of all the patients individually. The duration and
dosage of the corticosteroid therapy, daily or alternate
day regimen, and intravenous pulse steroid usage were
recorded separately. In addition to total steroid dose, total
daily or alternate day, total pulse steroid doses, and mean
daily steroid doses were calculated. High-dose steroid was
defined as >30 mg/day steroid usage at any time [8]. In our
clinic, we prefer daily and pulse steroid use with induction
treatment; and we prefer alternate day steroid use in the
maintenance treatment.
AVN was diagnosed according to routine clinical
practice, in symptomatic patients by plain X-ray and/or
magnetic resonance imaging (MRI).
2.1. Statistical analysis
Data analysis was made by SPSS 15.0 (SPSS Inc., Chicago,
IL, USA) and LogXact packet program, and P < 0.05 was
considered as statistical significance. Descriptive statistics
were given as mean ± standard deviation for numerical
data and as number and percent for qualitative data. To
compare numerical data between the AVN developed
group (AVN group) and the AVN nondeveloped group
(non-AVN group), an independent t-test was used; to
compare percentile data, chi-square test and Fischer’s
exact test were applied. Independent variables that were
significant after evaluation with single variable tests
were evaluated by single variable logistic regression and
exact logistic regression analysis to determine their odds
ratio. To determine significant variables’ effects on AVN
development, multiple logistic regression analysis was
applied.
3. Results
3.1. Demographic and clinical features
AVN was found in 11 of 127 (8.7%) SLE patients. Affected
AVN sides were the femoral head (73%), shoulder (27%),
knee (27%), and metatarsal head (9%). Multiple site
involvement was found in 5patients, and 24 sites were
affected in total. All AVN patients had osteoporosis and
were under bisphosphonates, calcium, and vitamin D
therapy.
Demographic features, diagnostic criteria, and
comorbid factors did not differ between the AVN group
and the non-AVN group; hyperlipidemia, however,
was significantly higher in the AVN group (P < 0.001).
Antiphospholipid syndrome, Raynaud’s phenomenon,
vasculitis, and SLEDAI, which were evaluated greatly in
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previous studies, were the same in both groups. However,
cushingoid body habitus, proteinuria, and osteoporosis
were significantly higher in the AVN group (P < 0.001, P <
0.013, and P < 0.03, respectively) (Table 1).
3.2. Corticosteroid therapy regimen
Corticosteroid was used by 122 of 127 (96.1%) SLE patients
during the treatment protocol (Table 2). All AVN group
patients had taken high-dose steroid therapy at some time
in their treatment duration. There was no difference in
corticosteroid usage ratio, corticosteroid usage duration,
total corticosteroid dosage, or total corticosteroid dose/
corticosteroid duration between patients with and
without AVN. However, daily corticosteroid usage, highdose steroid usage, and total daily steroid dosage were
significantly higher in patients with AVN than in those
without AVN. Patients without AVN had used alternate
day corticosteroid more frequently.
Based on the results of our study, hyperlipidemia,
osteoporosis, daily corticosteroid usage, total daily
corticosteroid dose, high dose corticosteroid therapy,
presence of proteinuria, and cushingoid body habitus
were statistically significant factors for the development
of AVN. According to the multivariate logistic regression
analysis, daily steroid usage was associated independently
with AVN occurrence (Table 3).
4. Discussion
In our study, hyperlipidemia, osteoporosis, daily
corticosteroid usage, total daily corticosteroid dosage,
persistent proteinuria, high-dose corticosteroid, and
cushingoid body habitus variables were found to be
individual risk factors for the development of AVN.
However, multivariate analysis showed that only daily
corticosteroid usage was a unique factor for AVN. From
another point of view, alternate day corticosteroid usage
was the protective factor for the development of AVN.
Interestingly, total corticosteroid dosage and corticosteroid
duration did not influence the development of AVN in this
study.
The relationship between corticosteroid usage and
AVN was first reported in renal transplant patients [9].
Thereafter, physicians noticed the relation between AVN
and SLE. In a large cohort of 1729 SLE patients with
symptomatic AVN, with more than 40 years of follow-up,
multivariate analysis had shown that only corticosteroids
were a primary risk for AVN [10]. Its prevalence changed
from 3% to 52% between symptomatic patients and
asymptomatic SLE patients [3]. AVN prevalence was
reported as 6% in a study from Turkey with 868 SLE cases
[11], the ratio of which was similar to our study (8.7%).
In this study, we only assessed symptomatic patients; thus
we can only say “at least” or “symptomatic” prevalence of
AVN in SLE patients.
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Table 1. Demographic and laboratory features of patients with and without AVN.
AVN (+) n = 11

AVN (-) n = 116

P-value

Female, n (%)

9 (82)

101 (87)

0.6

Age (mean ± SD)

34.5 (10.6)

39.1 (14.2)

0.3

Age at SLE diagnosis (mean ± SD)

28.5 (11.4)

32.3 (14.2)

0.4

Disease duration months (mean ± SD)

82.6 (74.3)

88.7 (67.5)

0.8

Malar rash, n (%)

6 (54.5)

54 (46.6)

0.8

Photosensitivity, n (%)

8 (72.7)

71 (61.2)

0.5

Oral ulcer, n (%)

1 (9.1)

31 (26.7)

0.3

Discoid rash, n (%)

0 (0)

12 (10.3)

0.6

Arthritis, n (%)

9 (81.8)

89 (76.7)

1.0

Neurologic involvement, n (%)

2 (18.2)

18 (15.5)

0.7

Renal involvement, n (%)

7 (63.6)

49 (42.2)

0.2

Serositis, n (%)

2 (18.2)

25 (21.6)

1.0

Hematologic involvement, n (%)

5 (45.5)

54 (46.6)

1.0

Raynaud’s phenomenon, n (%)

7 (6.6)

40 (36.0)

0.1

Vasculitis, n (%)

1 (9.1)

18 (15.7)

1.0

ANA, n (%)

11 (100)

114 (98.3)

1.0

ACA, n (%)

4 (36.4)

26 (22.4)

0.3

LA, n (%)

3 (27.3)

20 (17.4)

0.4

APL carriers, n (%)

6 (54.5)

31 (26.7)

0.1

APLS, n (%)

5 (45.5)

17 (54.8)

0.4

Persistent proteinuria ≥ 500 mg/day, n (%)

4 (36.4)

12 (10.3)

0.013

Anemia, n (%)

6 (54.5)

75 (64.7)

0.5

SLEDAI -2K (mean ± SD)

5.3 (3.5)

4.0 (4.8)

0.9

Comorbid diseases, n (%)
Hypertension
Diabetes mellitus
Coronary arterial disease
Hyperlipidemia
BMI ≥ 25
Smoking

5 (45.5)
0 (0)
0 (0)
4 (36.4)
7 (63.6)
4 (36.4)

27 (23.3)
11 (9.5)
4 (3.4)
11 (9.5)
57 (49.1)
29 (25.0)

0.06
0.6
1.0
<0.001
0.53
0.47

Cushingoid body habitus, n (%)

8 (72.7)

28 (24.3)

<0.001

Osteoporosis, n (%)

11 (100)

68 (66.7)

0.03

ACA: Anticardiolipin antibody positivity, ANA: Antinuclear antibody, APL carriers: antiphospholipid antibody
carriers, APLS: Cases whom have both anticardiolipin and/or lupus anticoagulant positivity and abortus,
thrombosis clinic, AVN: Avascular necrosis, BMI: body mass index, GFR: glomerular filtration rate, LA: Lupus
anticoagulant positivity.

Various conflict risk factors were defined in the
development of AVN in SLE patients. Some reports
stated that young age is a risk factor for AVN occurrence
[12–14]. Indeed, our patients with AVN were younger
than those without AVN; however, the difference was
not statistically significant. Hypertension, anemia, male
sex, and diabetes mellitus were the other potential risk

factors in the literature, but we did not find this kind of
relationship [11,15]. In those risk factors, hyperlipidemia
is an important risk factor for AVN, and some studies
suggested that antihyperlipidemic therapy may decrease
AVN risk [16,17]. In a pathogenetic view, corticosteroid
treatment may increase adipogenesis and fat hypertrophy
in bone marrow, and cause intraosseous pressure increase,
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Table 2. Steroid therapy method, dose, duration, and form in patients with and without AVN.
AVN (+), n = 11

AVN (-), n = 116

P-value

Corticosteroid usage, n (%)

11 (100)

111 (95.7)

0.7

Alternate day corticosteroid usage, n (%)

5 (45.5)

101 (91.0)

0.003

Daily corticosteroid usage, n (%)

11 (100)

54 (48.6)

0.001

Pulse corticosteroid usage, n (%)

4 (36.4)

42 (37.8)

1.0

High dose corticosteroid usage, n (%)

11 (100)

78 (70.3)

0.035

Corticosteroid duration (month) (mean ± SD)

75.1 (71.5)

81.6 (68.0)

0.9

Total corticosteroid dosage (gr) (mean ± SD)

19.6 (14.6)

21.4 (20.6)

0.8

Total corticosteroid dosage (mg) /
corticosteroid duration (day) = daily dosage (mean ± SD)

12.0 (7.5)

15.7 (22.5)

0.8

High-dose steroid: >30 mg/day steroid usage in any period of therapy; total steroid dose: total steroid dose used throughout
therapy duration; steroid duration: steroid therapy duration as month.
NA: Standard errors could not be estimated in exact logistic regression analysis. Inf: Infinitive. AVN: avascular necrosis, SLE:
systemic lupus erythematosus
Table 3. Multivariate logistic regression analysis of predictive factors of AVN in SLE.
Beta

Standard error

P-value

Odds ratio
(95% confidence interval)

Hyperlipidemia

1.549

0.973

0.237

4.71 (0.489–63.94)

Osteoporosis

0.379

NA

0.765

1.46 (0.156–inf)

Daily steroid usage

2.664

NA

0.014

14.35 (1.645–inf)

Total daily steroid dosage (gr)

-0.036

0.036

0.297

0.964 (0.889–1.03)

Persistent proteinuria ≥ 500 mg/day

0.520

0.865

0.836

1.682 (0.194–14.19)

High dose steroid

1.324

NA

0.251

3.758 (0.440–inf)

Cushingoid body habitus

0.452

0.855

0.916

1.571 (0.215–13.57)

interrupt blood flow to the femoral head, and result in
ischemic AVN [18]. In the present study, we found that
hyperlipidemia was more frequent in the AVN group,
but multivariate logistic regression analysis did not show
a strong relation between hyperlipidemia and AVN.
Cozen and Zhang et al. reported that AVN was frequent
in active, severe lupus patients [15,19]. However, it is
well known that severe organ involvement is associated
with high-dosage corticosteroid usage, and we did not
demonstrate this connection. Antiphospholipid syndrome
is another risk factor for AVN that was investigated by
most studies with conflicting results [20–23]. Our study
has not suggested this relation. Osteoporosis, a frequent
complication of corticosteroid and SLE, was found in all
of our AVN cases. All of them were also receiving therapy
for osteoporosis. High-dose corticosteroid may decrease
bone formation rapidly and permanently, and increase
bone resorption rapidly and temporarily [24]. Indeed,
corticosteroid induced osteoblast and osteocyte apoptosis
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may be the common mechanisms for osteoporosis and
AVN [25].
There was a strong association with daily corticosteroid
usage and AVN in our study. In 10 of a total of 16
reports, it was suggested that mean daily, maximum
daily, or high corticosteroid dosage was related with AVN
occurrence. Eight of 13 reports concerned with cumulative
corticosteroid dosage showed its relation with AVN [26].
The main result of our study was the superior effect for the
protection of AVN by usage of alternate day corticosteroid.
In a study that had compared long-term daily and alternate
day corticosteroid, although cumulative corticosteroid
dosage was higher in the alternate day group, corticosteroid
side effects such as moon face, psychiatric complications,
and regression in growth were low in the alternate day
group; furthermore, similar remission rates were obtained
for both groups [27]. In an animal study, AVN prevalence
was 45% versus 8% between the daily corticosteroid group
and intermittent corticosteroid group [28]. Although
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cumulative corticosteroid exposure was similar in both
groups, serum cortisol levels of the daily steroid group
were fully suppressed, but the intermittent group had
partial adrenal recovery. It was interpreted that partial
recovery of adrenal suppression in the intermittent steroid
group was the factor for low AVN risk. In ALL and renal
transplant patients, low AVN prevalence and low infection
risk were reported with alternate day corticosteroid
[29,30]. Due to the acceptable side effect profile and similar
clinical outcome of alternate day corticosteroid with daily
corticosteroid, we have routinely preferred alternate day
corticosteroid for long-term maintenance corticosteroid
therapy in our outpatient clinic for more than 20 years.
The main limitation was the design of the study. We
assessed SLE patients cross-sectionally; patient data was
recorded from patients and also from medical files. We
could not track patients prospectively, therefore, some of
the patients who had AVN and joint prosthesis may be
withdrawn from our follow-up. Hence, our AVN prevalence

should be accepted as an “at least” frequency. We assessed
only symptomatic patients through imaging. Thus, it is
possible to find a high prevalence when evaluating all
patients regularly by X-ray or MRI. Lastly, the number of
AVN cases may not be enough for an absolute conclusion
about possible AVN risk factors.
In conclusion, to decrease AVN risk in suitable
patients, alternate day steroid usage may be encouraged
in patients who are candidates for long-term maintenance
corticosteroid usage. However, physicians should keep
in mind that alternate day corticosteroid usage is also
closely related with other appropriate immunosuppressive
therapies.
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